BI-2536

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameBI-2536
Drug Alias NameBI-2536BI-2536-BS
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPolo like kinase 1 inhibitors
TargetsPolo like kinase 1
Therapy Area/IndicationsProstatic NeoplasmsCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustria +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. Kg
Active IndicationsN/A
Inactive IndicationsProstatic NeoplasmsCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksN/A